Zobrazeno 1 - 10
of 81
pro vyhledávání: '"E J, ter Borg"'
Autor:
J. C. Kelder, E. J. Ter Borg
Publikováno v:
Rheumatology International. 37:1153-1158
To investigate in a long-term study, the development of new extra-glandular manifestations (EGM) or associated auto-immune diseases (AID) from 1 year after establishing the diagnosis of primary Sjögren's syndrome (pSS). The primary goal was to exami
Autor:
Jwj Bijlsma, E-J. ter Borg
Publikováno v:
Clinical Rheumatology. 33:1015-1017
Osteoarthritis of the hands is very common, particularly in elderly people. Little is known though, is the subset of erosive osteoarthritis (EOA), which predicts a poorer prognosis and causes much more discomfort. Even less known is the fact that thi
Autor:
W. G. Boersma, J. Altenburg, E. J. Ter Borg, E. Vandenbroucke, J. M. M. Van Den Bosch, J.C. Grutters
Publikováno v:
Rheumatology International. 29:1499-1502
This case study reports a patient with severe interstitial pneumonitis, mild polyarthritis and polymyositis, accompanied by the presence of anti-Jo-1 antibodies diagnosed as antisynthetase syndrome. The concurrence of anti-Jo-1 with anti-Ro/SSA antib
Autor:
J. C. Kelder, E. J. Ter Borg
Publikováno v:
Clinical rheumatology. 35(3)
The primary goal was to investigate the differences in patients with and without polyarthritis (PA) in primary Sjogren's syndrome (pSS) in a clinical-based (real-life) setting, with respect to demographic characteristics, cumulative prevalence of oth
Autor:
J. W. G. Jacobs, E J ter Borg, Jwj Bijlsma, C van Booma-Frankfort, Jos N. Hoes, A A M Blaauw, G A van Albada-Kuipers, Suzanne M M Verstappen
Publikováno v:
Annals of the Rheumatic Diseases. 65:1506-1511
Objective: To investigate the prevalence and prognostic factors of joint surgery in a large cohort of patients with rheumatoid arthritis, whose treatment, clinical and radiographic data have been assessed at predefined points in time since disease on
Publikováno v:
Clinical Rheumatology. 26:529-532
Temporal arteritis (TA) may offer major complications, whilst high dosage of prednisone may result in serious side effects. We tried to identify a subgroup of TA, which can be treated with a lower dosage of prednisone. Retrospectively, clinical and l
Publikováno v:
International Journal of Clinical Medicine. :99-101
A lupus patient with a clinically quiescent disease stage will be described who had severely depressed C4 levels while levels of C3 en CH50 were normal. Additional testing revealed a homozygous C4Aisotype deficiency as the cause of the very low C4 le
Autor:
A A M Blaauw, E J ter Borg, Erik Buskens, J. W. G. Jacobs, Suzanne M M Verstappen, Jwj Bijlsma, H. Verkleij
Publikováno v:
Arthritis Care & Research. 51:488-497
Introduction Rheumatoid arthritis (RA) is a chronic disabling condition with, among other things, negative social and economic consequences for both the individual patient and society. Striking economic consequences are the diminished ability to perf
Autor:
Ale Algra, H. H. M. Houben, Roland Laan, E J ter Borg, R. N. J. de Nijs, J. W. G. Jacobs, P. L. M. van Oijen, George A W Bruyn, D. M. Hofman, A. A. A. Westgeest, Willem F. Lems, A. M. Huisman, J. W. J. Bijlsma
Publikováno v:
Rheumatology, 40, 1375-83
Rheumatology (Oxford, England), 40(12), 1375-1383. Oxford University Press
Rheumatology, 40, 12, pp. 1375-83
Rheumatology (Oxford, England), 40(12), 1375-1383. Oxford University Press
Rheumatology, 40, 12, pp. 1375-83
Item does not contain fulltext OBJECTIVE: This study was designed to determine whether the prevalence of vertebral deformities in patients with rheumatoid arthritis (RA) treated with corticosteroids (Cs) is higher than in RA patients not receiving Cs
Autor:
H. C. M. Haanen, Y Schenk, Aike A. Kruize, C van Booma-Frankfort, D. M. Hofman, H L M Brus, E. J. Ter Borg, A A M Blaauw, M. J. Van Der Veen, J. W. J. Bijlsma, G A van Albada-Kuipers, A H M Heurkens, C. H. M. Van Jaarsveld, J. W. G. Jacobs
Publikováno v:
Annals of the Rheumatic Diseases. 59:468-477
OBJECTIVES To compare three therapeutic strategies using slow acting antirheumatic drugs (SAARDs) in early rheumatoid arthritis (RA), for their disease modifying properties, toxicity, and lag time until treatment effect. METHODS Patients with recent